CDR-Life has formed a succesful partnership with Boehringer Ingelheim bringing together it’s antibody fragment expertise with Boehringer’s clinical development and marketing expertise.
We are open to partner with companies, academic collaborators, and individuals who share our vision and can help bring our innovations to patients.
The team has previously closed large deals and worked successfully in partnerships between pharma and biotech companies to bring new therapeutics into patients and onto the market.
«Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics…»
Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide. With Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s unique antibody fragment technology, the two companies are collaborating to advance CDR-Life’s preclinical candidate, with the aim of preserving sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim.
Our investors comprise both private individuals and institutions. They have extensive experience either in the biotechnology industry or in growing companies. As long-term strategic partners, we value their support much beyond the funding they provide.
To find out more about investment opportunities.